Smary Antisense oligonucleotides targeting p53 have been hailed as a potentially new technique for treating patients with cancer, and there have been encouraging reports of good patient tolerance in vivo and of antiproliferative effects in vitro. However, evidence is lacking that these oligonucleotides are acting via an antisense interaction to modulate p53 expression. We examined a phosphorothioate antisense oligonucleotide, directed against exon 10 of the TP53 gene, and a chimaeric phosphorothioate-phosphodiester oligonucleotide directed against the p53 translation initiation codon. Both failed to specifically suppress p53 protein production in a cell-free assay system or to have any effect on mutant p53 expression by human pancreatic cancer cell lines. Antiproliferative effects were apparent, especially with the phosphorothioate antisense oligonucleotide, but this was independent of the p53 status of the cells (mutant, wild-type or absent) and also occurred with the control (sense and randomised) oligonucleotides. The most dramatic antiproliferative effects were seen with the .control' phosphorothioate oligonucleotides. These findings suggest that the antiproliferative effects of some antisense oligonucleotides may be unrelated to expression of the gene they have been designed to target. The antisense oligonucleotide approach involves the exogenous administration of short, synthetic, single-stranded oligonucleotide sequences, generally DNA based, which are taken up relatively inefficiently by the cell and released into the cytoplasm. They are thought to act predominantly by blocking translation of mRNA (reviewed in Murray and Crockett, 1992; Toulme, 1992; Carter and Lemoine, 1993; Nellen and Lichtenstein, 1993; Prins et al., 1993) . Sequences complementary to the protein-coding part of the mRNA are thought to act mainly by causing cleavage by RNAse H, which specifically degrades the RNA component of RNA-DNA hybrids. Sequences which target the 5' untranslated region are thought to prevent attachment and sliding of the 40S ribosomal subunit by steric hindrance, and those which bind close to the AUG initiation codon may prevent further assembly of the translation initiation complex.
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Keyworis: antisense: oligonucleotide; p53; cancer therapy Modulation of gene expression by naturally occurring antisense interactions is well documented in prokaryotes and may occur naturally in eukaryotic cells (reviewed in Murray and Crockett, 1992; Thomas, 1992; Nellen and Lichtenstein, 1993) . Antisense techniques have also been devised to selectively reduce gene expression by the sequence-specific binding of complementary nucleic acids. Such techniques have become powerful tools for selectively reducing the expression of target genes in vitro, and there is increasing interest in the possibility of using the same technology in vivo for therapeutic purposes.
The antisense oligonucleotide approach involves the exogenous administration of short, synthetic, single-stranded oligonucleotide sequences, generally DNA based, which are taken up relatively inefficiently by the cell and released into the cytoplasm. They are thought to act predominantly by blocking translation of mRNA (reviewed in Murray and Crockett, 1992; Toulme, 1992; Carter and Lemoine, 1993; Nellen and Lichtenstein, 1993; Prins et al., 1993) . Sequences complementary to the protein-coding part of the mRNA are thought to act mainly by causing cleavage by RNAse H, which specifically degrades the RNA component of RNA-DNA hybrids. Sequences which target the 5' untranslated region are thought to prevent attachment and sliding of the 40S ribosomal subunit by steric hindrance, and those which bind close to the AUG initiation codon may prevent further assembly of the translation initiation complex.
Most work has been done with oligonucleotides modified to increase their stability and lipid solubility, for example by replacement of the phosphodiester linkage in the sugarphosphate backbone to increase nuclease resistance. A phosphorothiorate linkage (in which the oxygen atom is replaced by a sulphur atom) is a commonly used modification. Chimaeric oligonucleotides have the modified linkage for only part of the molecule, usually the 5' and 3' ends, since intracellular degradation is mainly due to exonucleases (Giles and Tidd, 1992; Ortigao et al., 1992; Toulme, 1992 (Nigro et al., 1989; Levine, 1992; Levine et al., 1994) . Wild-type p53 is dispensable for normal cell growth and metabolism, albeit at the cost of an increased susceptibility to malignant change (Malkin et al., 1990; Srivastava et al., 1990; Donehower et al., 1992; Harvey et al., 1993) . There is also evidence for a gene dosage effect so that complete suppression of mutant p53 expression may not be necessary for a significant anti-tumour effect, especially if there is some residual wild-type gene expression (Schafer et al., 1994) . Lastly, there is evidence that p53 expression may be modulated naturally by the endogenous production of antisense RNA transcripts (Khochbin et al., 1992) .
Phosphorothiate oligonucleotides have now been given systemically to animals and humans (Iversen et al., 1992; Spinolo et al., 1992a) . In a phase I clinical trial a phosphorothioate oligonucleotide targeting p53 exon 10, OL(1) p53, was given by continuous infusion for up to 10 days and was well tolerated with few adverse effects (Spinolo et al., 1992b , Bishop et al., 1993 Bayever et al., 1993 Bayever et al., , 1994 . This oligonucleotide has been reported to have a significant antiproliferative effect on AML (Bayever et al., 1994) and pancreatic cancer cells (Bayever and Haines, 1993) in vitro, and, when given by systemic infusion to patients, to inhibit the growth of their leukaemic blasts in vitro (Spinolo et al., 1992b; Bishop et al., 1993; Bayever et al., 1993 Bayever et al., , 1994 .
Exciting as these reports are, no evidence has been provided that the oligonucleotide is acting via an antisense interaction or that it modulates p53 expression. We have investigated this oligonucleotide in pancreatic cancer cell lines, since expression of mutant p53 is thought to be an important early event in pancreatic carcinogenesis (Barton et al., 1991; Wylie et al., 1993) and because pancreatic cancer is notoriously resistant to currently available cancer therapies (Alanen and Joensuu, 1993; Ellis and Cunningham, 1994 (Spinolo et al., 1992b; Bayever and Haines 1993; Bishop et al., 1993; Bayever et al., 1993 Bayever et al., , 1994 RNA polymerase or TNT V7 RNA polymerase (0.5 p1l), 1 mM amino acid mixture minus methionine (0.5 p1), RNasin ribonuclease inhibitor (0.5 p1) and [GE_S3S L-methionme (2 p1).
The mixture was added to 500 ng of DNA template with or without the appropriate olgonucleotide and diethylpyrocarbonate (DEPC)-treated water to a final volume of 25 p1. The reaction mix was the incubated at 30-C for 1-2 h. An aliquot was mixed with an equal vohlume of 2 x sample loading buffer and boied for 2 mm to denature the protein.
Six microlitres of each sample was electrophoresed on a 10% denaturing polyacrylamide (acrylamide-bisacrylamide, 29:1) gel overnight at a constant current of 3.5 mA. The gel was to cut to size, fixed, soaked in Amplify (Amersham International), dried and exposed to radiographic film for 2-6 h.
Three plasmids were used as template. The plasmid pSP65p53 has full-length wild-type TP53 cDNA cloned downstream to an SP6 RNA polymerase promoter. In addition to full-length p53 protein, in vitro transcription/ translation is known to produce a 46 kDa protein as a result of translation initiation at the methionine residue at nucleotide 332 and other smaler internally initiated peptides (Harlow et al., 1985 (AsPC-l and CaPan-2) (Barton et al., 1991; Ruggeri et al., 1992; Kalthoff et al., 1993; Simon et al., 1994; Berrozpe et al., 1994) . Each was treated with two anisense oligonucleotides, Bip53as and OLlp53as, which target the AUG initiation codon and exon 10 of p53 mRNA respectively. Each cell ine -was also treated with sense and sequence-randomised controls (BipS3s, Bip53rand, OLlpS3s and OLlp53rand respectively). Four different oligonucleotide concentrations (0.5piM, 1pM, 5pm, 10IpM) were used.
Within 24 h of exposure to the oligonucleotides profound morphological changes were noted in cells growing in OLlp53s (Figure 1) . To a lesser extent the same morphological changes were seen in cells growing in the presence of OLlpS3rand, although at 0.5 pM concentration of OLlp53rand the cells appeared relatively unharmed. All cell lnes were affected regardle of TP53 status, although to slightly different extents, and the effects were obviously dose related and became more noticeable as time went on. The cells clumpe together, rounded up and lost attachment to the tissue culture dishes and there were fewer cells present (as reflected in the MTT findings). However, many of the 'rounded-up' cells appeared still to be viable since they could be re-established in culture after removal from the oligonucleotide solution and washing.
These morphological effects were consistently seen in all the cell lines being prepared for MTI assay but not in cells being prepared for ELISAs. Cells for ELISAs were grown for . IT WrA_=_ 16 h in serum-deficient (0.5% FCS) culture medium and were fully attached to the culture dishes before the oligonucleotide was added, whereas the cells for MTI assay were plated out directly into medium containing the oligonucleotides, having been removed from large culture dishes by standard versene/ trypsin treatment. Others have observed that the effects of oligonucleotide administration may vary depending on how Figure 3 and representative results in Figure 4 . No difference in p53 level was detectable 12, 24 or 48 h after oligonucleotide was added, regardless of the oligonucleotide added or the final oligonucleotide concentration, even at high concentrations of Bip53 oligonucleotides. Since the morpholocal effects of the OLlp53 oligonucleotides were only apparent when cells were plated out directly into the oligonucleotide-containing medium after trypsin/versene treatment, we repeated the ELISA measurements on cells pasaged in this manner and still observed no apparent effect on p53 protein levels.
Effects of oligomucleotides on in vitro transcription/translation
Using the plasmid pSP65p53 as template we analysed the effects of different concentrations of oligonucleotide on in vitro transcription/translation using the TNT coupled reticulocyte lysate system (Promega). In the absence of oligonucleotide, p53 protein was readily produced, in addition to a 46 kDa and other smaller protein products from alternative internal initiation sites. Slightly less protein was produced overall when any oligonucleotide was present in the reaction mix. In addition, a dose-related inhibition of p53 protein production (and smaler internally initiated proteins) was apparent with the antisense oligonucleotide Bip53as but not for its v&nwe and randomirti cntralc Riniq snnd RinvsrnnA 750 100
Suppression was detectable at 0.5 9M concentration and was almost complete at a concentration of 4 9AM ( Figure 5 ). However, at 4 9AM concentration BipS3as also significantly inhibited luciferase protein production ( Figure 5 ) and slightly inhibited AP2 protein production ( Figure 6 ). Both these proteins are encoded by genes to which BipS3as has no significant complementarity.
The antisense oligonucleotide OLlpS3as and its controls OLlp53s and OLlpS3rand all appeared to suppress p53 protein (and smaller intemally initiated proteins) production to some extent. At a concentration of 0.5 9iM, OLlp53as significntly suppressed and OLlp53rand completely suppressed p53 protein production. At 1 9AM concentration p53 protein production was also markedly suppressed by OLlp53s (Figure 7) . However, the same effects were apparent when luciferase or AP2 DNA was transcribed and translated in the presence of these oligonucleotides (Figures 6 and   7 Flgwe 4 Effect of different concentrations of oligonucleotides on p53 levels measured by ELISA using the cell line PT45. In the range studied p53 levels were directly proportional to the absorbance at 492 nm. The results are shown here uncorrected for total protein concentration. Therefore, p53 levels generally appear to rise because the cell number and hence total protein content of the lysate steadily increases with time. Cell number and total protein concentrations were similar to untreated control cells except when cells were plated directly into OLlp53s or OLlp53rand. In these instances, the cell number and total protein concentration (and p53 concentration) of the lysate were proportionally less than similar cultures owing to the non-specific toxicity described in the text. Corrected for total protein level, the p53 concentration was similar to that of untreated control cells. For clarity, error bars are omitted from all but the 'no oligonucleotide' control curves. p53 status (mutant, wild-type or absent), and in most cell lines more dramatic antiproliferative effects were seen with the control oligonucleotides OLlp53s and OLlp53rand. These control oligonucleotides also appeared to affect cell-cell or cell-substratum interactions after trypsin/versene treatment at relatively low concentrations, causing the cells to round up, clump together and lose attachment to the culture dish.
These results, and particularly the results of the in vitro transcription/translation experiments, strongly suggest that the encouraging antiproliferative effects observed with OLlp53as by other investigators are not due to a specific antisense interaction leading to modulation of p53 expression. Fully phosphorothioate-substituted oligonucleotides are now known to have undesirable features, notably a tendency to non-specific toxicity owing to non-sequence-specific protein binding (including various growth factors, protein kinase C and transcription factors, slow cellular uptake and activation of RNAse H at sites other than the main target sequence (Stein and Krieg, 1994) . Runs of four or more Gs in phosphorothioate oligonucleotides have also been documented to produce non-specific growth inhibition independent of any aniisense effect (Cohen, 1993; Stein and Krieg, 1994 RNAse H, by the time exon 10 is reached translation of the p53 message is almost complete. It is possible that minimally truncated p53 proteins which still contain the important highly conserved regions and which retain significant wildtype p53 activity might be produced. Furthermore, p53 protein detected in acute myeloid leukaemia (AML) blast cells is usually wild type not mutant (Fenaux et al., 1991; Slingerland et al.. 1991; Sugimoto et at., 1991; Hu et al., 1992 ). According to current models of p53 activity, a reduction in expression of wild-type p53 would be predicted to result in loss of growth control not growth suppression, as reported in these experiments with haematopoietic cells.
The results of experiments using the chimaenrc phosphorothioate-phosphodiester antisense oligonucleotide Bip53as, directed against the p53 translation initiation codon, support the contention that great care must be exercised in designing and interpreting the results of antisense experiments. We found that Bip53as did suppress p53 protein production by in vitro transcription/translation but also suppressed protein production from unrelated control luciferase and AP2 genes. However, in a pancreatic cell line expressing mutant p53 there was no demonstrable suppression of p53 protein production even at very high concentrations (100 M). A mild non-specific antiproliferative effect was seen at higher concentrations similar to that seen with the control oligonucleotides Bip53s and Bip53rand and regardless of the p53 status of the cells. Although Bip53as has been reported to down-regulate p53 expression in CML cells (Bi et al., 1994) , our results suggest that the expression of other genes might also be modulated and (as for the OLlp53 oligonucleotides) that these are not necessarily predictable on the basis of sequence complementan'ty or homology with the oligonucleotide. Interestingly, in the CML cells, suppression of p53 expression using Bip53as stimulated colony formation and promoted proliferation, supporting the notion that suppression of wildtype p53 expression might be growth stimulatory in certain circumstances (Bi et al., 1994 
